MHRA Prior knowledge of Adverse Drug Reactions relating to all the covid 19 vaccines

Dear Medicines and Healthcare Products Regulatory Agency, I have found evidence of prior knowledge of Adverse Drug Reactions in a document regarding Artificial intelligence use to track the expected ADR's. https://ted.europa.eu/udl?uri=TED%3ANOTI...

Please Explain. Confirm or Deny, so I can present to my MP.

United Kingdom-London: Software package and information systems

2020/S 207-506291

Contract award notice

Results of the procurement procedure

Supplies

Legal Basis:
Directive 2014/24/EU
Section I: Contracting authority

I.1)
Name and addresses
Official name: MHRA Buyer Organisation
Town: London
NUTS code: UK UNITED KINGDOM
Postal code: E14 4PU
Country: United Kingdom
E-mail: [email address]
Telephone: +44 2030806000
Internet address(es):
Main address: https://www.gov.uk/government/organisati...
I.4)
Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5)
Main activity
Health
Section II: Object

II.1)
Scope of the procurement
II.1.1)
Title:
SafetyConnect — AI

II.1.2)
Main CPV code
48000000 Software package and information systems
II.1.3)
Type of contract
Supplies
II.1.4)
Short description:
The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.

II.1.6)
Information about lots
This contract is divided into lots: no
II.1.7)
Total value of the procurement (excluding VAT)
Value excluding VAT: 1 500 000.00 GBP
II.2)
Description
II.2.2)
Additional CPV code(s)
48000000 Software package and information systems
II.2.3)
Place of performance
NUTS code: UK UNITED KINGDOM
II.2.4)
Description of the procurement:
The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.

II.2.5)
Award criteria
Price
II.2.11)
Information about options
Options: no
II.2.13)
Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)
Additional information
Section IV: Procedure

IV.1)
Description
IV.1.1)
Type of procedure
Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below
The procurement falls outside the scope of application of the directive
Explanation:
For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool.

Strictly necessary — it is not possible to retrofit the MHRA’s legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine. Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.

Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.

Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far.

IV.1.3)
Information about a framework agreement or a dynamic purchasing system
IV.1.8)
Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)
Administrative information
IV.2.8)
Information about termination of dynamic purchasing system
IV.2.9)
Information about termination of call for competition in the form of a prior information notice
Section V: Award of contract

A contract/lot is awarded: yes
V.2)
Award of contract
V.2.1)
Date of conclusion of the contract:
14/09/2020
V.2.2)
Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators: no
V.2.3)
Name and address of the contractor
Official name: Genpact (UK) Ltd
Town: London
NUTS code: UK UNITED KINGDOM
Country: United Kingdom
The contractor is an SME: no
V.2.4)
Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot: 1 500 000.00 GBP
V.2.5)
Information about subcontracting
Section VI: Complementary information

VI.3)
Additional information:
VI.4)
Procedures for review
VI.4.1)
Review body
Official name: Medicines and Healthcare Products Agency
Town: London
Country: United Kingdom
VI.5)
Date of dispatch of this notice:
19/10/2020

Yours faithfully, Peter Harland

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Peter Harland
<[FOI #826075 email]> Sent: Tuesday, January 25,
2022 5:10:04 PM To: MHRA Customer Services Subject: Freedom of Information
request - MHRA Prior knowledge of Adverse Drug Reactions relating to all
the covid 19 vaccines Dear Medicines and Healthcare Products Regulatory
Agency, I have found evidence of prior knowledge of Adverse Drug Reactions
in a document regarding Artificial intelligence use to track the expected
ADR's.
https://eur01.safelinks.protection.outlo...
Please Explain. Confirm or Deny, so I can present to my MP. United
Kingdom-London: Software package and information systems 2020/S 207-506291
Contract award notice Results of the procurement procedure Supplies Legal
Basis: Directive 2014/24/EU Section I: Contracting authority I.1) Name and
addresses Official name: MHRA Buyer Organisation Town: London NUTS code:
UK UNITED KINGDOM Postal code: E14 4PU Country: United Kingdom E-mail:
[email address] Telephone: +44 2030806000 Internet address(es):
Main address:
https://eur01.safelinks.protection.outlo...
I.4) Type of the contracting authority Ministry or any other national or
federal authority, including their regional or local subdivisions I.5)
Main activity Health Section II: Object II.1) Scope of the procurement
II.1.1) Title: SafetyConnect — AI II.1.2) Main CPV code 48000000 Software
package and information systems II.1.3) Type of contract Supplies II.1.4)
Short description: The MHRA urgently seeks an Artificial Intelligence (AI)
software tool to process the expected high volume of Covid-19 vaccine
Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’
reaction text are missed. II.1.6) Information about lots This contract is
divided into lots: no II.1.7) Total value of the procurement (excluding
VAT) Value excluding VAT: 1 500 000.00 GBP II.2) Description II.2.2)
Additional CPV code(s) 48000000 Software package and information systems
II.2.3) Place of performance NUTS code: UK UNITED KINGDOM II.2.4)
Description of the procurement: The MHRA urgently seeks an Artificial
Intelligence (AI) software tool to process the expected high volume of
Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details
from the ADRs’ reaction text are missed. II.2.5) Award criteria Price
II.2.11) Information about options Options: no II.2.13) Information about
European Union funds The procurement is related to a project and/or
programme financed by European Union funds: no II.2.14) Additional
information Section IV: Procedure IV.1) Description IV.1.1) Type of
procedure Award of a contract without prior publication of a call for
competition in the Official Journal of the European Union in the cases
listed below The procurement falls outside the scope of application of the
directive Explanation: For reasons of extreme urgency under Regulation
32(2)(c) related to the release of a Covid-19 vaccine MHRA have
accelerated the sourcing and implementation of a vaccine specific AI tool.
Strictly necessary — it is not possible to retrofit the MHRA’s legacy
systems to handle the volume of ADRs that will be generated by a Covid-19
vaccine. Therefore, if the MHRA does not implement the AI tool, it will be
unable to process these ADRs effectively. This will hinder its ability to
rapidly identify any potential safety issues with the Covid-19 vaccine and
represents a direct threat to patient life and public health. Reasons of
extreme urgency — the MHRA recognises that its planned procurement process
for the SafetyConnect programme, including the AI tool, would not have
concluded by vaccine launch. Leading to a inability to effectively monitor
adverse reactions to a Covid-19 vaccine. Events unforeseeable — the
Covid-19 crisis is novel and developments in the search of a Covid-19
vaccine have not followed any predictable pattern so far. IV.1.3)
Information about a framework agreement or a dynamic purchasing system
IV.1.8) Information about the Government Procurement Agreement (GPA) The
procurement is covered by the Government Procurement Agreement: yes IV.2)
Administrative information IV.2.8) Information about termination of
dynamic purchasing system IV.2.9) Information about termination of call
for competition in the form of a prior information notice Section V: Award
of contract A contract/lot is awarded: yes V.2) Award of contract V.2.1)
Date of conclusion of the contract: 14/09/2020 V.2.2) Information about
tenders Number of tenders received: 1 The contract has been awarded to a
group of economic operators: no V.2.3) Name and address of the contractor
Official name: Genpact (UK) Ltd Town: London NUTS code: UK UNITED KINGDOM
Country: United Kingdom The contractor is an SME: no V.2.4) Information on
value of the contract/lot (excluding VAT) Total value of the contract/lot:
1 500 000.00 GBP V.2.5) Information about subcontracting Section VI:
Complementary information VI.3) Additional information: VI.4) Procedures
for review VI.4.1) Review body Official name: Medicines and Healthcare
Products Agency Town: London Country: United Kingdom VI.5) Date of
dispatch of this notice: 19/10/2020 Yours faithfully, Peter Harland
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #826075 email] Is [MHRA request email] the wrong
address for Freedom of Information requests to Medicines and Healthcare
Products Regulatory Agency? If so, please contact us using this form:
https://eur01.safelinks.protection.outlo...
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Our Ref: FOI 22/438

Dear Peter Harland,

RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000

Thank you for your enquiry which we received on 26th January 2022.

I confirm that your request is now being handled under the Freedom of Information Act and you should receive a reply within 20 working days from our date of receipt.

If you need to contact us again about this request, please quote the reference number above.

Please be aware that we publish FOIs replies and these are redacted and are located on our website at the following link below.
https://www.gov.uk/government/collection...

Kind Regards,

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000

show quoted sections

Pharmacovigilanceservice, Medicines and Healthcare Products Regulatory Agency

1 Attachment

Dear Mr Harland,

Please find attached the response to your FOI request.

Kind regards,

FOI Team
Vigilance and Risk Management of Medicines Division
Medicines and Healthcare Products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU

show quoted sections

Dear Medicines and Healthcare Products Regulatory Agency,

Please pass this on to the person who conducts Freedom of Information reviews.

I am writing to request an internal review of Medicines and Healthcare Products Regulatory Agency's handling of my FOI request 'MHRA Prior knowledge of Adverse Drug Reactions relating to all the covid 19 vaccines'.

My question involves the words "prior knowledge ", to which you have not answered at all, I would also point out that
"urgently seeks an Artificial Intelligence (AI) software tool to process the "EXPECTED"* high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) " and ensure that no details from the ADRs’ reaction text are missed."
using the key word here is "expected"* in this sentence and is obviously what I am asking about, "high volume" only adds more to my accusation that this document proves prior knowledge of Vaccine damage.
That makes no sense in any other context other than the one implied by it's very meaning.
I will be taking this issue further.
A full history of my FOI request and all correspondence is available on the Internet at this address: https://www.whatdotheyknow.com/request/m...

Yours faithfully,

Peter Harland

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Peter Harland
<[FOI #826075 email]> Sent: Tuesday, February 15,
2022 7:09:29 PM To: MHRA Customer Services Subject: Internal review of
Freedom of Information request - MHRA Prior knowledge of Adverse Drug
Reactions relating to all the covid 19 vaccines Dear Medicines and
Healthcare Products Regulatory Agency, Please pass this on to the person
who conducts Freedom of Information reviews. I am writing to request an
internal review of Medicines and Healthcare Products Regulatory Agency's
handling of my FOI request 'MHRA Prior knowledge of Adverse Drug Reactions
relating to all the covid 19 vaccines'. My question involves the words
"prior knowledge ", to which you have not answered at all, I would also
point out that "urgently seeks an Artificial Intelligence (AI) software
tool to process the "EXPECTED"* high volume of Covid-19 vaccine Adverse
Drug Reaction (ADRs) " and ensure that no details from the ADRs’ reaction
text are missed." using the key word here is "expected"* in this sentence
and is obviously what I am asking about, "high volume" only adds more to
my accusation that this document proves prior knowledge of Vaccine damage.
That makes no sense in any other context other than the one implied by
it's very meaning. I will be taking this issue further. A full history of
my FOI request and all correspondence is available on the Internet at this
address:
https://eur01.safelinks.protection.outlo...
Yours faithfully, Peter Harland
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #826075 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Internal Review of FOI 22/438

Dear Peter Harland,

Thank you for your email.

We confirm that an internal review will be carried out on FOI 22/438. We normally aim to respond to requests for internal review within 20 working days of receipt. However, due to high volumes of queries we are currently receiving related to COVID-19 please be aware that responses may take longer than usual.  

Kind Regards  

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf,
London E14 4PU
Telephone 020 3080 6000

show quoted sections

Dear Medicines and Healthcare Products Regulatory Agency,

Please pass this on to the person who conducts Freedom of Information reviews.

I am writing to request an internal review of Medicines and Healthcare Products Regulatory Agency's handling of my FOI request 'MHRA Prior knowledge of Adverse Drug Reactions relating to all the covid 19 vaccines'.
I have asked a very specific question regarding the MHRA having prior knowledge of vaccine adverse reactions as quoted in your own publications, please be aware that these documents have already been entered into court proceedings regarding this serious crime, fore knowledge of a known health risk and the withholding such information is contrary to the law. I have issued copies of all my evidence to my MP and have lodged a complaint regarding this serious allegation.

"For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool.

Strictly necessary — it is not possible to retrofit the MHRA’s legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine. Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.

Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.

Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far."

Yours faithfully,

Peter Harland

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Peter Harland
<[FOI #826075 email]> Sent: Thursday, February 24,
2022 11:38:12 AM To: MHRA Customer Services Subject: Internal review of
Freedom of Information request - MHRA Prior knowledge of Adverse Drug
Reactions relating to all the covid 19 vaccines Dear Medicines and
Healthcare Products Regulatory Agency, Please pass this on to the person
who conducts Freedom of Information reviews. I am writing to request an
internal review of Medicines and Healthcare Products Regulatory Agency's
handling of my FOI request 'MHRA Prior knowledge of Adverse Drug Reactions
relating to all the covid 19 vaccines'. I have asked a very specific
question regarding the MHRA having prior knowledge of vaccine adverse
reactions as quoted in your own publications, please be aware that these
documents have already been entered into court proceedings regarding this
serious crime, fore knowledge of a known health risk and the withholding
such information is contrary to the law. I have issued copies of all my
evidence to my MP and have lodged a complaint regarding this serious
allegation. "For reasons of extreme urgency under Regulation 32(2)(c)
related to the release of a Covid-19 vaccine MHRA have accelerated the
sourcing and implementation of a vaccine specific AI tool. Strictly
necessary — it is not possible to retrofit the MHRA’s legacy systems to
handle the volume of ADRs that will be generated by a Covid-19 vaccine.
Therefore, if the MHRA does not implement the AI tool, it will be unable
to process these ADRs effectively. This will hinder its ability to rapidly
identify any potential safety issues with the Covid-19 vaccine and
represents a direct threat to patient life and public health. Reasons of
extreme urgency — the MHRA recognises that its planned procurement process
for the SafetyConnect programme, including the AI tool, would not have
concluded by vaccine launch. Leading to a inability to effectively monitor
adverse reactions to a Covid-19 vaccine. Events unforeseeable — the
Covid-19 crisis is novel and developments in the search of a Covid-19
vaccine have not followed any predictable pattern so far." Yours
faithfully, Peter Harland
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #826075 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

1 Attachment

Internal Review of FOI 22/438

Dear Peter Harland,

Thank you for your email.

Please find attached the response to your Internal Review.

Kind Regards  

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf,
London E14 4PU
Telephone 020 3080 6000

show quoted sections

Dear MHRA Customer Services,
This FOI 22/438 was nothing to do with me, I don't understand why you would reply with an unrelated request.

Yours sincerely,

Peter Harland

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Peter Harland
<[FOI #826075 email]> Sent: Thursday, February 24,
2022 5:32:30 PM To: MHRA Customer Services Subject: Internal review of
Freedom of Information request - MHRA Prior knowledge of Adverse Drug
Reactions relating to all the covid 19 vaccines Dear MHRA Customer
Services, This FOI 22/438 was nothing to do with me, I don't understand
why you would reply with an unrelated request. Yours sincerely, Peter
Harland -----Original Message----- Internal Review of FOI 22/438 Dear
Peter Harland, Thank you for your email. Please find attached the response
to your Internal Review. Kind Regards   MHRA Customer Experience Centre
Communications and engagement team Medicines and Healthcare products
Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #826075 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Peter Harland

Thanks for highlighting and we have filed this.

You internal review request is still in hand.

Kind Regards

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf,
London E14 4PU
Telephone 020 3080 6000

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

1 Attachment

  • Attachment

    Internal Review of FOI 22 438 RE Internal review of Freedom of Information request MHRA Prior knowledge of Adverse Drug Reactions relating to all the covid 19 vaccines.txt

    4K Download View as HTML

Dear Mr Peter Harland,

Thank you for your email.

Please find attached acknowledgment sent to you previously for this internal review.

We will pass below to include to the attached to the relevant team.

Kind Regards

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf,
London E14 4PU
Telephone 020 3080 6000

show quoted sections